The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...

Black people who have cystic fibrosis may not get diagnosed as quickly as they should. Here are 3 times it gets misdiagnosed ...

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNPCurrent treatment ...

Nasal polyps are benign (non-cancerous) growths that develop inside the nose or sinuses. Common causes of nasal polyps include asthma, allergies, and chronic sinus infections. Nasal polyps are ...

The absorption of neffy may be affected in patients with underlying structural or anatomical nasal conditions (eg, nasal polyps, history of nasal surgery). In these patients, epinephrine products ...

The FDA has expanded the approval of Dupixent to include adolescents aged 12 to 17 years with inadequately controlled CRSwNP.

The biotech industry is poised for significant growth, fueled by advanced technologies, the increased commercialization of ...

In a recent study investigators established that extended dupilumab therapy-up to three years-is highly effective in the ...

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

The FDA recently approved the first needle-free epinephrine product (neffy), an alternative to injectable epinephrine (EpiPen ...

GSK receives Japanese MHLW approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Thursday, August 29, 2024, 09:00 Hrs [IST] GSK plc announc ...

The Food and Drug Administration (FDA) has expanded the approval of Dupixent ® (dupilumab) to include add-on maintenance treatment of adolescent patients aged 12 to 17 years with inadequately ...